comparative efficacy of sildenafil and bosentan in newborn with persistent pulmonary hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20260321006

Enrollment

Registered

2026-03-21

Start date

2023-09-26

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

persistant pulmonary hypertension PPHN

Interventions

Group A is for Sildenafil treatment group,Group B is for Bosentan treatment group

Treatment,Treatment

sildenafil,bosentan

Eligibility

Sex/Gender

All

Age

1 Days to 10 Days

Inclusion criteria

Inclusion criteria: 1. Less than 10 days of age of either gender, greater than 34 weeks of gestational age 2. Echocardiographic finding according to operational definitions 3. New-borns with sign and symptoms of PPHN not related to any secondary cause

Exclusion criteria

Exclusion criteria: 1. congenital heart diseases 2. pneumonia 3. active seizures 4. pneumothorax

Design outcomes

Primary

Measure	Time frame
Efficacy of Sildenafil and Bosentan in newborn with Persistent Plumonary Hypertension will be documented and it will help to manage PPHN effectively in future. 1 year observation	—

Secondary

Measure	Time frame
no no no	—

Countries

Pakistan

Contacts

Public Contactdr abdul qayyum

post grauate resident

drabdulqayyumchtha@gmail.com03213194995

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026